Interleukin 4 promotes anti-inflammatory macrophages that clear cartilage debris and inhibits osteoclast development to protect against osteoarthritis

Copyright © 2021 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 229(2021) vom: 11. Aug., Seite 108784
1. Verfasser: von Kaeppler, Ericka P (VerfasserIn)
Weitere Verfasser: Wang, Qian, Raghu, Harini, Bloom, Michelle S, Wong, Heidi, Robinson, William H
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, U.S. Gov't, Non-P.H.S. Inerleukin-4 Inflammation Macrophage Myeloid Osteoarthritis Osteoclast IL4 protein, human Il4 protein, mouse mehr... Il4ra protein, mouse Receptors, Cell Surface STAT6 Transcription Factor Stat6 protein, mouse Interleukin-4 207137-56-2
LEADER 01000naa a22002652 4500
001 NLM326740937
003 DE-627
005 20231225195242.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2021.108784  |2 doi 
028 5 2 |a pubmed24n1089.xml 
035 |a (DE-627)NLM326740937 
035 |a (NLM)34126239 
035 |a (PII)S1521-6616(21)00121-2 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a von Kaeppler, Ericka P  |e verfasserin  |4 aut 
245 1 0 |a Interleukin 4 promotes anti-inflammatory macrophages that clear cartilage debris and inhibits osteoclast development to protect against osteoarthritis 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 16.09.2021 
500 |a Date Revised 16.09.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2021 Elsevier Inc. All rights reserved. 
520 |a OBJECTIVE: Osteoarthritis (OA), the leading cause of joint failure, is characterized by breakdown of articular cartilage and remodeling of subchondral bone in synovial joints. Despite the high prevalence and debilitating effects of OA, no disease-modifying drugs exist. Increasing evidence, including genetic variants of the interleukin 4 (IL-4) and IL-4 receptor genes, implicates a role for IL-4 in OA, however, the mechanism underlying IL-4 function in OA remains unknown. Here, we investigated the role of IL-4 in OA pathogenesis 
520 |a METHODS: Il4-, myeloid-specific-Il4ra-, and Stat6-deficient and control mice were subjected to destabilization of the medial meniscus to induce OA. Macrophages, osteoclasts, and synovial explants were stimulated with IL-4 in vitro, and their function and expression profiles characterized 
520 |a RESULTS: Mice lacking IL-4, IL-4Ra in myeloid cells, or STAT6 developed exacerbated cartilage damage and osteophyte formation relative to WT controls. In vitro analyses revealed that IL-4 downregulates osteoarthritis-associated genes, enhances macrophage phagocytosis of cartilage debris, and inhibits osteoclast differentiation and activation via the type I receptor 
520 |a CONCLUSION: Our findings demonstrate that IL-4 protects against osteoarthritis in a myeloid and STAT6-dependent manner. Further, IL-4 can promote an immunomodulatory microenvironment in which joint-resident macrophages polarize towards an M2 phenotype and efficiently clear pro-inflammatory debris, and osteoclasts maintain a homeostatic level of activity in subchondral bone. These findings support a role for IL-4 modulation of myeloid cell types in maintenance of joint health and identify a pathway that could provide therapeutic benefit for osteoarthritis 
650 4 |a Journal Article 
650 4 |a Research Support, U.S. Gov't, Non-P.H.S. 
650 4 |a Inerleukin-4 
650 4 |a Inflammation 
650 4 |a Macrophage 
650 4 |a Myeloid 
650 4 |a Osteoarthritis 
650 4 |a Osteoclast 
650 7 |a IL4 protein, human  |2 NLM 
650 7 |a Il4 protein, mouse  |2 NLM 
650 7 |a Il4ra protein, mouse  |2 NLM 
650 7 |a Receptors, Cell Surface  |2 NLM 
650 7 |a STAT6 Transcription Factor  |2 NLM 
650 7 |a Stat6 protein, mouse  |2 NLM 
650 7 |a Interleukin-4  |2 NLM 
650 7 |a 207137-56-2  |2 NLM 
700 1 |a Wang, Qian  |e verfasserin  |4 aut 
700 1 |a Raghu, Harini  |e verfasserin  |4 aut 
700 1 |a Bloom, Michelle S  |e verfasserin  |4 aut 
700 1 |a Wong, Heidi  |e verfasserin  |4 aut 
700 1 |a Robinson, William H  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 229(2021) vom: 11. Aug., Seite 108784  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:229  |g year:2021  |g day:11  |g month:08  |g pages:108784 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2021.108784  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 229  |j 2021  |b 11  |c 08  |h 108784